Medartis stock initiated with Neutral rating by UBS on priced-in growth

Published 31/07/2025, 09:08
Medartis stock initiated with Neutral rating by UBS on priced-in growth

Investing.com - UBS initiated coverage on Medartis Holding AG (SWX:MED) with a Neutral rating and a price target of CHF90.00 on Thursday.

The Swiss orthopedic implant manufacturer, which specializes in extremities and holds approximately 4% global market share, is expected to continue gaining market share according to UBS’s analysis.

UBS projects Medartis will achieve an organic sales compound annual growth rate of approximately 14% from 2024 to 2029, outpacing the broader market’s growth of around 7%.

This growth outlook is primarily driven by Medartis’ expanding product portfolio and geographical reach, particularly through increased adoption of the Keri’s TOUCH prosthesis.

Despite positive growth prospects, UBS believes Medartis’ current valuation at 29x 2025E EV/EBITDA already prices in "near perfect execution of the growth story," while cash conversion is expected to remain structurally lower than peers due to the company’s higher growth trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.